Lemonade Inc vs Synopsys, Inc. — how do they compare? Lemonade Inc trades at $46.35 (market cap $3.63B), while Synopsys, Inc. trades at $507.41 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 26.3× Lemonade Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Synopsys, Inc. for 71 Days on average.
| LMND | SNPS | |
|---|---|---|
Market Cap | $3.63B | $95.39B |
Volume | 1,544,794 | 3,374,903 |
Sector | Financials | Technology |
52-Week High | $96.57 | $534.56 |
52-Week Low | $43.91 | $367.70 |
Typical Hold Time | 27 Days | 71 Days |
Enterprise Value | $3.49B | $102.62B |
Signals from Pluang's Aura AI — not financial advice
LMND trades at $46.64, down 0.41% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains strong at 32% year-over-year in Q2 2026, with improving loss ratios and gross profit up 76%. The company is expanding geographically and expects its first EBITDA-positive quarter in late 2026, supported by AI-driven efficiency gains.
While LMND shows promising growth and path to profitability, the stock faces headwinds from persistent net losses, high valuation multiples, and mixed analyst sentiment. The consensus price target of $67.00 suggests 44% upside potential, but investors must weigh growth prospects against ongoing cash burn and competitive pressures in the insurtech space.
Synopsys (SNPS) stock trades at $505.76, up 0.61% today, near its 52-week high. The technical picture is bullish with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, the company reported strong quarterly earnings beats and robust revenue growth, driven by AI partnerships with OpenAI and Amazon. Analyst sentiment is overwhelmingly positive with a 93% buy rating and a consensus price target of $572.54, indicating significant upside potential.
The outlook for SNPS is highly favorable, supported by AI-driven demand for chip design software and strategic acquisitions like Ansys. Key risks include high valuation multiples and integration challenges from recent deals. Investors should focus on execution of growth initiatives and monitor competitive pressures in the semiconductor design software market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →